Unknown

Dataset Information

0

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.


ABSTRACT: Investigate the safety and tolerability of AZD5363 and define a recommended dose for evaluation in Japanese patients with advanced solid malignancies.AZD5363 was administered orally as a single dose, and then the dose was escalated to twice daily (bid) in separate continuous (every day) and intermittent (4 days on, 3 days off [4/3] or 2 days on, 5 days off [2/5]) dosing schedules to reach recommended doses defined by dose-limiting toxicity (DLT). Doses for continuous, 4/3, and 2/5 intermittent dosing schedules were 80-400, 360-480, and 640 mg, respectively, and were informed by results from an equivalent study in Caucasian patients.Forty-one patients received AZD5363. DLTs were only experienced with continuous dosing. 97.6 % of patients reported at least one adverse event (AE); most common were diarrhea (78.0 %), hyperglycemia (68.3 %), nausea (56.1 %), and maculopapular rash (56.1 %). Grade ?3 AEs were reported by 63.4 % of patients. Exposure of AZD5363 was generally dose proportional for both single and multiple doses. Single-dose pharmacokinetics of AZD5363 was generally predictive of multiple-dose pharmacokinetics. Confirmed partial responses were reported by two patients, both of whom were Akt1 (E17K) mutation positive. One patient in the 480 mg bid 4/3 dosing cohort maintained partial response for >2 years.Intermittent dosing of AZD5363 was more tolerable than continuous dosing. 480 mg bid intermittent 4/3 dosing for AZD5363 monotherapy was selected for further investigation. Preliminary evidence of antitumor activity was observed. Akt1 (E17K) is a potent driver mutation that may predict clinical response to AZD5363.

SUBMITTER: Tamura K 

PROVIDER: S-EPMC4819940 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6501043 | biostudies-literature
| S-EPMC5010592 | biostudies-literature
| S-EPMC3130141 | biostudies-literature
| S-EPMC5907623 | biostudies-literature
| S-EPMC9700577 | biostudies-literature
| S-EPMC4317910 | biostudies-literature
| S-EPMC7982615 | biostudies-literature
| S-EPMC8541992 | biostudies-literature
| S-EPMC8018307 | biostudies-literature
| S-EPMC10712727 | biostudies-literature